Table 4.
Feature | Cluster 0 (n = 11) | Cluster 1 (n = 7) | Cluster 2 (n = 6) | p-Value † | Post-Hoc ‡ |
---|---|---|---|---|---|
Men, n (%) | 6 (66.67%) | 5 (62.50%) | 4 (57.14%) | 0.9999 †† | - |
Women, n (%) | 3 (33.33%) | 3 (37.50%) | 3 (42.86%) | - | - |
Age (years) | 64.33 ± 6.44 | 60.88 ± 7.30 | 63.57 ± 11.80 | 0.6948 | - |
Age at onset (years) | 57.22 ± 7.41 | 50.63 ± 9.77 | 58.14 ± 12.89 | 0.2882 | - |
Disease duration (years) | 7.11 ± 3.48 | 10.25 ± 5.73 | 5.43 ± 2.23 | 0.0912 | - |
Hoehn and Yahr scale score | 1.67 ± 0.50 | 2.25 ± 0.71 | 1.57 ± 0.53 | 0.0669 | - |
UPDRSA | 1.33 ± 0.50 | 2.00 ± 1.07 | 1.86 ± 1.35 | 0.3650 | - |
UPDRSM | 4.11 ± 2.37 | 6.13 ± 2.36 | 4.00 ± 1.29 | 0.1023 | - |
Velocity | 105.35 ± 5.85 | 143.25 ± 8.76 | 116.63 ± 6.40 | <0.0001 * | A < C< B |
Cadence | 112.00 ± 4.08 | 127.07 ± 7.50 | 129.06 ± 3.52 | <0.0001 * | A < B,C |
Stride time (s) | 1.07 ± 0.04 | 0.95 ± 0.06 | 0.93 ± 0.02 | <0.0001 * | C,B < A |
Stride length (cm) | 113.15 ± 6.08 | 135.68 ± 7.03 | 108.52 ± 5.10 | <0.0001 * | C,A < B |
Single support (s) | 0.41 ± 0.02 | 0.37 ± 0.03 | 0.36 ± 0.01 | 0.0009 * | C,B < A |
Double support (s) | 0.27 ± 0.01 | 0.20 ± 0.03 | 0.21 ± 0.03 | <0.0001 * | B,C < A |
Spatial symmetry | 36.69 ± 0.67 | 39.59 ± 1.07 | 38.66 ± 1.41 | 0.0031 * | - |
Values are presented as means ± standard deviation. † Significant difference between the intervention and control group in one-way analysis of variance (ANOVA). ‡ Post-hoc test by Bonferroni procedure after one-way ANOVA. †† p-value were analyzed by Exact-test. * p < 0.05. UPDRSA, a subsection of the Unified Parkinson’s Disease Rating Scale (UPDRS) score that includes the “walking and balance” and “freezing” parts of the UPDRS II assessment for activities of daily living; UPDRSM, a subsection of the UPDRS score that includes the “gait”, “postural stability”, “posture”, and “body bradykinesia” parts of the UPDRS III motor assessment; A, Cluster 0; B, Cluster 1; C, Cluster 2.